
X
NICE rejects Opdivo in head and neck cancer – before it gains marketing approval
https://pharmaphorum.com/news/nice-rejects-opdivo-head-neck-cancer-gains-marketing-approval/
Checkpoint inhibitor drug set to be fourth competitor in PD-1/PD-L1 market